Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib

Detalles Bibliográficos
Autores principales: Selaru, P, Tang, Y, Huang, B, Polli, A, Wilner, KD, Donnelly, E, Cohen, DP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351315/
https://www.ncbi.nlm.nih.gov/pubmed/26841346
http://dx.doi.org/10.1111/cts.12388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351315/
https://www.ncbi.nlm.nih.gov/pubmed/26841346
http://dx.doi.org/10.1111/cts.12388

Ejemplares similares